JP2012529433A5 - - Google Patents

Download PDF

Info

Publication number
JP2012529433A5
JP2012529433A5 JP2012514221A JP2012514221A JP2012529433A5 JP 2012529433 A5 JP2012529433 A5 JP 2012529433A5 JP 2012514221 A JP2012514221 A JP 2012514221A JP 2012514221 A JP2012514221 A JP 2012514221A JP 2012529433 A5 JP2012529433 A5 JP 2012529433A5
Authority
JP
Japan
Prior art keywords
xaa
alkyl
aryl
cyclic peptide
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012514221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012529433A (ja
JP5805632B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/037589 external-priority patent/WO2010144344A2/en
Publication of JP2012529433A publication Critical patent/JP2012529433A/ja
Publication of JP2012529433A5 publication Critical patent/JP2012529433A5/ja
Application granted granted Critical
Publication of JP5805632B2 publication Critical patent/JP5805632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012514221A 2009-06-08 2010-06-07 メラノコルチン受容体に特異的なペプチド Active JP5805632B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18492909P 2009-06-08 2009-06-08
US61/184,929 2009-06-08
PCT/US2010/037589 WO2010144344A2 (en) 2009-06-08 2010-06-07 Melanocortin receptor-specific peptides

Publications (3)

Publication Number Publication Date
JP2012529433A JP2012529433A (ja) 2012-11-22
JP2012529433A5 true JP2012529433A5 (enExample) 2013-07-25
JP5805632B2 JP5805632B2 (ja) 2015-11-04

Family

ID=43309425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514221A Active JP5805632B2 (ja) 2009-06-08 2010-06-07 メラノコルチン受容体に特異的なペプチド

Country Status (14)

Country Link
US (4) US8846601B2 (enExample)
EP (1) EP2440227B1 (enExample)
JP (1) JP5805632B2 (enExample)
KR (1) KR101726893B1 (enExample)
CN (2) CN102458436B (enExample)
AU (1) AU2010259008C1 (enExample)
BR (1) BRPI1009644B1 (enExample)
CA (1) CA2761607C (enExample)
EA (1) EA020959B1 (enExample)
IL (1) IL216843A (enExample)
MX (1) MX2011013117A (enExample)
NZ (1) NZ596617A (enExample)
WO (1) WO2010144344A2 (enExample)
ZA (1) ZA201200112B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2761607C (en) 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
AU2010321738B2 (en) * 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
PL3539551T3 (pl) 2011-12-29 2022-02-21 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
AU2014227712B2 (en) 2013-03-15 2018-08-02 Rhythm Pharmaceuticals, Inc. Peptide compositions
WO2015162287A1 (en) * 2014-04-25 2015-10-29 Phi Pharma Sa Keratan sulfate specific transporter molecules
CN104436159A (zh) * 2014-12-09 2015-03-25 天津医科大学眼科医院 一种新型滴眼液对治疗干眼的用途
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
FI3356386T3 (fi) 2015-09-30 2024-05-16 Rhythm Pharmaceuticals Inc Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
US11174298B2 (en) * 2016-11-09 2021-11-16 James P. Tam Preparation and use of ginsentides and ginsentide-like peptides
BR112020019128A2 (pt) * 2018-03-23 2021-01-12 Palatin Technologies, Inc. Formulação farmacêutica de liberação em trato gastrointestinal inferior; formulação farmacêutica de liberação no trato gastrointestinal inferior preparada por um processo; processo; formulação de liberação modificada; composição farmacêutica adequada para administração oral para tratamento de uma doença inflamatória intestinal; e método de tratamento de doença inflamatória intestinal (ibd) em um paciente humano com ibd
CA3096055A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
CN115279390A (zh) * 2020-02-03 2022-11-01 帕拉丁科技公司 反向酰胺连接的促黑素受体特异性环状肽
PE20221328A1 (es) * 2020-02-03 2022-09-09 Palatin Technologies Inc Peptidos ciclicos especificos de receptores unidos a diamina
CN114890958B (zh) * 2022-02-23 2023-10-20 四川警察学院 双光子染料化合物、其制备方法及其应用
CN115521356B (zh) * 2022-08-17 2024-04-02 桂林医学院 一种具有美白功效的多肽及其应用
CN119529031B (zh) * 2024-11-27 2025-12-05 润辉生物技术(威海)有限公司 一种环肽衍生物及其制备方法与应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
CN1246868A (zh) 1996-12-17 2000-03-08 扇形支撑剑桥有限公司 黑皮素
AU739469B2 (en) 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
BR0009497A (pt) 1999-03-29 2002-01-15 Procter & Gamble Ligantes de receptores de melanocortina
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
WO2003006620A2 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001052880A1 (en) 2000-01-18 2001-07-26 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
AU2001261363A1 (en) 2000-05-09 2001-11-20 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
EP1315750B1 (en) * 2000-08-30 2007-02-14 F. Hoffmann-La Roche Ag Cyclic peptides having melanocortin-4 receptor agonist activity
PL362003A1 (en) 2000-09-27 2004-10-18 The Procter & Gamble Company Melanocortin receptor ligands
US7345144B2 (en) 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
EP1409521A2 (en) 2001-07-12 2004-04-21 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US20060122121A1 (en) 2002-11-14 2006-06-08 Lipton James M Modified alpha-MSH peptides and derivatives thereof
US7135548B2 (en) 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
WO2004075783A2 (en) 2003-02-26 2004-09-10 Landry Donald W A method for stabilizing blood pressure in hemodialysis subjects
JP2007524584A (ja) 2003-05-09 2007-08-30 ノボ ノルディスク アクティーゼルスカブ 肥満の治療に使用するペプチド
MXPA05011830A (es) 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
JP2006527772A (ja) 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン3受容体(mc3r)作用薬ペプチドの用途
CA2530024A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
CN1809372A (zh) * 2003-06-19 2006-07-26 伊莱利利公司 黑皮质素受体4(mc4)激动剂及其用途
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
WO2005019212A1 (en) 2003-08-20 2005-03-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
KR20060089874A (ko) * 2003-09-30 2006-08-09 노보 노르디스크 에이/에스 신규 멜라노코르틴 수용체 작용제
DK1689349T3 (da) 2003-11-24 2013-12-02 Clinuvel Pharmaceuticals Ltd Fremgangsmåde til induktion af melanogenese i mennesker med variante MC1R-alleler
WO2005060985A1 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
EP1732586A1 (en) 2004-03-29 2006-12-20 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion
DK1789076T3 (en) 2004-08-04 2016-04-11 Clinuvel Pharmaceuticals Ltd METHODS for inducing melanogenesis in a subject
KR101255140B1 (ko) 2004-10-25 2013-04-22 얀센 바이오테크 인코포레이티드 멜라노코르틴 수용체 결합 모방체, 조성물, 방법 및 용도
CN101052649A (zh) 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的肽类
US20110098213A1 (en) 2004-11-04 2011-04-28 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
WO2006048449A2 (en) 2004-11-04 2006-05-11 Novo Nordisk A/S Mc4r selective peptides and their use in the treatment of obesity
JP2008519009A (ja) 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
US20080207493A1 (en) 2005-03-17 2008-08-28 Novo Nordisk A/S Compounds for Use in the Treatment of Obesity
WO2007008684A2 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Ligands of melanocortin receptors
EP2236151B1 (en) * 2005-07-08 2012-05-23 Ipsen Pharma Melanocortin receptor ligands
WO2007009894A2 (en) 2005-07-18 2007-01-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP1957096A4 (en) 2005-08-29 2012-03-21 Palatin Technologies Inc CYCLIC PEPTIDE INSULATION BY SPRAY DRYING
US8114844B2 (en) * 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
HUE035074T2 (en) 2006-08-31 2018-05-02 Clinuvel Pharmaceuticals Ltd Alpha-MSH derivatives for the treatment of photodermatoses
CN101177450A (zh) * 2006-11-09 2008-05-14 武汉聚奇医药科技有限公司 引发男性阴茎勃起和提高女性性欲的短肽
EP2106406A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
EP2101822A2 (en) 2007-01-18 2009-09-23 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
JP2010517943A (ja) 2007-01-18 2010-05-27 ノボ・ノルデイスク・エー/エス 肥満の治療に使用される新規ペプチド
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
CN101302246B (zh) * 2007-05-09 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 黑色素皮质激素受体七肽类激动剂及其制备方法和用途
WO2008156677A2 (en) 2007-06-15 2008-12-24 Ipsen Pharma S.A.S. Cyclic peptide melanocortin receptor ligands
CN103316345B (zh) 2007-11-05 2016-05-18 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用
CA2727317C (en) * 2008-06-09 2015-02-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CA2761607C (en) * 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides

Similar Documents

Publication Publication Date Title
JP2012529433A5 (enExample)
JP2013511553A5 (enExample)
JP2013511554A5 (enExample)
JP2016523241A5 (enExample)
RU2014137107A (ru) Пептидомиметические макроциклы
CN102711802B (zh) 肽glp‑2激动剂
JP2020502051A5 (enExample)
EP0804463A1 (de) Neurokinin (tachykinin)-antagonisten
JP2013533864A5 (enExample)
MY161450A (en) Double-acylated glp-1 derivatives
JP2009527499A5 (enExample)
RU2010123466A (ru) Пептидное производное - миметик эритропоэтина и его фармацевтические соли, их получение и применение
KR20140014081A (ko) 아밀로이드 피브릴 형성과 관련된 증상 치료용 디펩티드 유사체
RU2006144279A (ru) Пептидные соединения
JP2019501214A5 (enExample)
RS54722B1 (sr) Agonisti v1a receptora
CN105658670A (zh) 肽-低聚尿素嵌合化合物及其使用方法
JP2018531284A6 (ja) 環状ポリペプチド、それらを得る方法、及びその治療的使用
JP2018531284A (ja) 環状ポリペプチド、それらを得る方法、及びその治療的使用
AU744425B2 (en) 20(s) camptothecin glycoconjugates
CA3206846A1 (en) Anti-infective bicyclic peptide ligands
JP2020189806A (ja) 複合体
RU2007118385A (ru) Контрастные агенты для направлений доставки во внеклеточный матрикс
CN106279357A (zh) 双[(乙酰-Lys(AA)-OBzl)吲哚]乙烷,其制备,活性和应用
CN107602450B (zh) 氨基酸骨架类新型cxcr4拮抗剂及其制备与生物医学应用